95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine

Marcellin, Patrick; Lau, G.K.K.; Bonino, Ferruccio; Farci, Patrizia; Hadziyannis, S.; Jin, Runyan; Lu, Zhongmin; Piratvisuth, Teerha; Germanidis, G.; Pluck, Nigel

doi:10.1016/s0168-8278(04)90095-5

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Newer nucleoside analogues may offer lower resistance rates but are currently restricted to use in patients with established lamivudine resistance. Recent data suggest that the use of pegulated interferon may offer a greater chance of sustained viral suppression for HBeAg negative CHB (Cooksley et al, 2003;Marcellin et al, 2004), however this requires confirmation.…”

Section: Resultsmentioning

confidence: 99%

Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients

Bell

Lau

Thompson

et al. 2005

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients

Bell

Lau

Thompson

et al. 2005

Journal of Clinical Virology

View full text Add to dashboard Cite

“…A new phase III study of 537 HBeAg negative, predominantly Asian patients, comparing peginterferon alfa-2a (40KD), either alone or in combination with lamivudine for 72 weeks, showed a higher normalization of serum ALT levels and a higher rate of reduction in serum HBV DNA level less than 10,000 copies/ml in the peginterferon alfa-2a (40 KD) groups (Table 1 ). Loss of HBsAg with or without anti-HBs seroconversion and ≥ 2-point reduction in HAI index are also higher in patients receiving peginterferon alfa-2a (40 KD) (Table 1 ) 46 . New data from a Phase III study of 814 predominantly Asian patients with peginterferon alfa-2a (40KD), either alone or in combination with lamivudine, will be available soon.…”

Section: Immunomodulatory Treatments Of Chronic Hepatitis B Infectionmentioning

confidence: 99%

Advances in immunomodulating therapy of HBV infection

Hui

Lau²

2005

Int. J. Med. Sci.

View full text Add to dashboard Cite

Patients with chronic hepatitis B virus (HBV) infection have a higher risk of developing liver cirrhosis and hepatocellular carcinoma. Interferon-α, lamivudine and adefovir dipivoxil are the three approved treatment for chronic HBV infection and offers the only means of preventing the development of these complications. However, the efficacy of these agents, in terms of loss of Hepatitis B e antigen with or without seroconversion to Hepatitis B e antibody, normalization of serum alanine transaminase levels, loss of serum HBV DNA, and improvement in liver histology can only be achieved in 20-30% of those treated. Long-term treatment with either lamivudine or adefovir dipivoxil can result in the development of drug resistant mutants leading to an increased length of treatment with additional nucleoside analogues. These limitations of the current antiviral therapies underline the need for alternative therapies. Specific and nonspecific immunotherapeutic strategies to restore effective virus-specific T cell responses in those with chronic HBV infection offers an interesting alternative approach. These immunotherapeutic therapies include the adoptive transfer of HBV immunity, pegylated interferon and therapeutic vaccine therapies.

show abstract

“…Results of a large study ( n = 537) comparing 48 weeks of Peg‐IFN α ‐2a with and without lamivudine to lamivudine alone, in the treatment of HBeAg‐negative patients, showed that the combination of Peg‐IFN α ‐2a with lamivudine did not improve response rates over Peg‐IFN α ‐2a monotherapy. At the end of 24 weeks follow‐up virologic response was achieved in 43% Peg‐IFN α ‐2a‐treated patients vs. 44% of patients treated with the combination therapy [38].…”

Section: Interferon‐α Therapymentioning

confidence: 99%

Immunomodulatory therapy for chronic hepatitis B virus infection

Sprengers

Janssen²

2004

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is one of the most prevalent viral pathogens of man with around 350 million chronically infected patients. It has been postulated that in persistently infected individuals the HBV-specific immune response is too weak to eliminate HBV from all infected hepatocytes, but sufficiently strong to continuously destroy HBV-infected hepatocytes and to induce chronic inflammatory liver disease. The primary aim in the treatment of chronic hepatitis B is to induce sustained disease remission and prevent serious complications like liver failure and/or hepatocellular carcinoma. The recent emergence of drug-resistant HBV mutants and post-treatment relapse as a consequence of nucleoside analogue monotherapy emphasizes that the principal goal should be to stimulate a successful immune response. In this paper we will focus on the immune response to HBV and we will review reported data on immunotherapeutic strategies like immunomodulatory drugs (cytokines and Thymic derivates) and vaccine therapies using currently available recombinant anti-HBV vaccines, lipopeptide-based T cell vaccine and newly developed genetic vaccines.

show abstract

95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine

Cited by 6 publications

References 0 publications

Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients

Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients

Advances in immunomodulating therapy of HBV infection

Immunomodulatory therapy for chronic hepatitis B virus infection

Contact Info

Product

Resources

About